A Comprehensive Review on the Efficacy of Anti-CD20 Therapies in Pemphigus Treatment

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 May 24

PMID 38784354

Authors

Arshiya Khan

Adarshlata Singh

Bhushan Madke

Drishti M Bhatt

Shivani D Jangid

Affiliations

Soon will be listed here.

Abstract

Pemphigus, an autoimmune blistering disorder, poses significant therapeutic challenges due to dysregulated B cells and the involvement of CD20. This review assesses the efficacy of anti-CD20 therapies, including rituximab, ofatumumab, ocrelizumab, and obinutuzumab, in pemphigus treatment. Mechanisms of action, clinical studies, and safety profiles were analyzed, revealing diverse impacts on disease severity. B cell depletion emerged as a pivotal factor, disrupting the autoimmune process and reducing pathogenic antibodies. Varied efficacy and safety profiles among agents underscore the need for personalized treatment strategies guided by biomarkers. Challenges such as resistance and long-term safety concerns necessitate continued research and vigilance. In clinical practice, insights from this review inform nuanced, tailored approaches for improved pemphigus management. The dynamic landscape of emerging therapies and personalized medicine emphasizes the need for ongoing research and strategic clinical decision-making. This review is a foundation for future investigations, providing insights for clinicians and researchers in optimizing pemphigus treatment.

References

Tobinai K, Klein C, Oya N, Fingerle-Rowson G . A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther. 2016; 34(2):324-356. PMC: 5331088. DOI: 10.1007/s12325-016-0451-1. View

De Seze J, Maillart E, Gueguen A, Laplaud D, Michel L, Thouvenot E . Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023; 14:1004795. PMC: 10076836. DOI: 10.3389/fimmu.2023.1004795. View

Scarpone R, Francuzik W, Worm M, Heine G . Therapy Changes During Pemphigus Management: A Retrospective Analysis. Front Med (Lausanne). 2020; 7:581820. PMC: 7732666. DOI: 10.3389/fmed.2020.581820. View

Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D . Management of pemphigus vulgaris: challenges and solutions. Clin Cosmet Investig Dermatol. 2015; 8:521-7. PMC: 4622091. DOI: 10.2147/CCID.S75908. View

Tavakolpour S . Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. Int Immunopharmacol. 2017; 53:133-142. DOI: 10.1016/j.intimp.2017.10.027. View

Kuriyama K, Kitamura Y, Tsuji T, Nishikawa R, Nagata H, Ohshiro M . Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. Curr Probl Cancer. 2021; 46(2):100813. DOI: 10.1016/j.currproblcancer.2021.100813. View

Zakka L, Shetty S, Ahmed A . Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb). 2012; 2(1):17. PMC: 3510419. DOI: 10.1007/s13555-012-0017-3. View

Klufas D, Amerson E, Twu O, Clark L, Shinkai K . Refractory pemphigus vulgaris successfully treated with ofatumumab. JAAD Case Rep. 2020; 6(8):734-736. PMC: 7369462. DOI: 10.1016/j.jdcr.2020.05.034. View

Yuan H, Pan M, Chen H, Mao X . Immunotherapy for Pemphigus: Present and Future. Front Med (Lausanne). 2022; 9:901239. PMC: 9240651. DOI: 10.3389/fmed.2022.901239. View

10.

Smets I, Giovannoni G . Derisking CD20-therapies for long-term use. Mult Scler Relat Disord. 2021; 57:103418. DOI: 10.1016/j.msard.2021.103418. View

11.

Ly S, Nedosekin D, Wong H . Review of an Anti-CD20 Monoclonal Antibody for the Treatment of Autoimmune Diseases of the Skin. Am J Clin Dermatol. 2023; 24(2):247-273. PMC: 9838371. DOI: 10.1007/s40257-022-00751-7. View

12.

Izumi K, Bieber K, Ludwig R . Current Clinical Trials in Pemphigus and Pemphigoid. Front Immunol. 2019; 10:978. PMC: 6509547. DOI: 10.3389/fimmu.2019.00978. View

13.

Lycke J, Svenningsson A . Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary. Mult Scler. 2022; 28(8):1177-1178. PMC: 9189590. DOI: 10.1177/13524585221101138. View

14.

Aryanian Z, Balighi K, Daneshpazhooh M, Karamshahi E, Hatami P, Goodarzi A . Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study. Int Immunopharmacol. 2021; 96:107755. DOI: 10.1016/j.intimp.2021.107755. View

15.

Merrill J, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2009; 62(1):222-33. PMC: 4548300. DOI: 10.1002/art.27233. View

16.

Owen C, Stewart D . Obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspective. Ther Adv Hematol. 2015; 6(4):161-70. PMC: 4530370. DOI: 10.1177/2040620715586528. View

17.

Lamberts A, Euverman H, Terra J, Jonkman M, Horvath B . Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases. Front Immunol. 2018; 9:248. PMC: 5827539. DOI: 10.3389/fimmu.2018.00248. View

18.

Pavlasova G, Mraz M . The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. PMC: 7271567. DOI: 10.3324/haematol.2019.243543. View

19.

Lim S, Beers S, French R, Johnson P, Glennie M, Cragg M . Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2009; 95(1):135-43. PMC: 2805725. DOI: 10.3324/haematol.2008.001628. View

20.

Zhang B . Ofatumumab. MAbs. 2010; 1(4):326-31. PMC: 2726602. DOI: 10.4161/mabs.1.4.8895. View